Intellia to price IPO of 5 million shares between $16.00 and $18.00

Credit Suisse, Jefferies and Leerink Partners, Wedbush PacGrow assist

By Devika Patel

Knoxville, Tenn., April 27 – Intellia Therapeutics, Inc. will sell 5 million common shares in its initial public offering with a 30-day greenshoe of 750,000 additional shares, according to a Form S-1/A filed Wednesday with the Securities and Exchange Commission. The deal was announced on April 11.

The shares will be sold at a price expected to fall between $16.00 and $18.00 per share.

Credit Suisse Securities (USA) LLC, Jefferies LLC and Leerink Partners LLC are the bookrunners. Wedbush PacGrow is the co-manager.

Regeneron Pharmaceuticals, Inc. will invest $50 million, and Novartis Institutes for Biomedical Research, Inc. will invest $5 million.

Proceeds will be used for research and development, to progress product candidates, for working capital and for other general corporate purposes.

The gene editing company is based in Cambridge, Mass. The company intends to list its common stock on the Nasdaq stock exchange under the symbol “NTLA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.